Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits antiviral and... more
Product information "Efavirenz"
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits antiviral and anticancer activities. Efavirenz binds to wild-type and mutant HIV-1 RTs (Ki= 2.93nM and 3.85-56.5nM, respectively). It inhibits wild-type and mutant HIV-1 viral replication in MT-4 human T lymphoid cells (IC95s = 1.5-1,500 nM). Efavirenz also prevents RNA plus-strand initiation with an IC50 value of 17nM. Efavirenz is an anti-HIV drug, commonly used in combination therapy for AIDS treatment. It is part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. In various cancer cell lines, Efavirenz inhibits cellular proliferation and increases activation of p53. CARD8 inflammasome senses HIV-1 protease activity. In HIV-infected cells, CARD8 cannot detect the virus because the viral protease remains inactive as a subunit of unprocessed Gag-Pol polyprotein. HIV-1-specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), such us Efavirenz, can trigger CARD8 sensing because they bind to HIV-1 Pol and enhance intracellular Gag-Pol polyprotein dimerization, which causes premature viral protease activation. Treating HIV-1-infected macrophages and CD4+ T cells with NNRTIs leads to CARD8-mediated caspase-1 activation and pyroptotic cell death. Induction of the CARD8 inflammasome activation has led to rapid clearance of latent HIV-1 in patient CD4+ T cells after virus reactivation. Appearance: White to off-white solid. Solubility: Soluble in DMSO (10mg/ml), DMF (20mg/ml) or ethanol (10mg/ml). Insoluble in water. InChi Key: XPOQHMRABVBWPR-UHFFFAOYSA-N Smiles: ClC1=CC=C2C([C@@](C#CC3CC3)(C(F)(F)F)OC(N2)=O)=C1
Keywords: | DMP 266, EFV, L-743,726 |
Supplier: | AdipoGen Life Sciences |
Supplier-Nr: | AG-CR1-3751 |
Properties
Application: | Antiviral, Reverse transcriptase inhibitor |
MW: | 315.7 D |
Formula: | C14H9ClF3NO2 |
Purity: | >98% (HPLC) |
Format: | Solid |
Database Information
CAS : | 154598-52-4| Matching products |
KEGG ID : | K24802 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | +20°C (International: +20°C) |
Signal Word: | Danger |
GHS Hazard Pictograms: |
|
H Phrases: | H302, H319, H360, H372, H410 |
P Phrases: | P201,P202,P260,P264,P270,P273,P280,P314,P330,P391,P301+P312,P305+P351+P338,P308+P313,P337+P313,P405,P501 |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed